Patterns of Progression on Crizotinib for ALK+ NSCLC
Corey Langer, MD, provides insight on patterns of progression on ALK-targeted therapy, resistance mutations, and triggers to change to another agent in non–small cell lung cancer.
Corey Langer, MD, provides insight on patterns of progression on ALK-targeted therapy, resistance mutations, and triggers to change to another agent in non–small cell lung cancer.
